Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Pascale, Dielenseger"'
Autor:
Pascale Dielenseger, Carla Matta, Antoine Angelergues, Paule Augereau, Dominique Berton, Michel Fabbro, Claire Falandry, Philippe Follana, Laurence Gladieff, Florence Joly, Jean-Emmanuel Kurtz, Marie-Ange Mouret-Reynier, Antonin Schmitt, Florian Scotté, Coralie Marjollet, Frédéric Selle
Publikováno v:
Bulletin Infirmier du Cancer. 23:45-58
Autor:
Frédéric Selle, Jean-Jacques Boffa, Gabriel Etienne, Antoine Angelergues, Paule Augereau, Dominique Berton, Pascale Dielenseger, Michel Fabbro, Claire Falandry, Philippe Follana, Laurence Gladieff, Florence Joly, Jean-Emmanuel Kurtz, Carla Matta, Marie-Ange Mouret-Reynier, Antonin Schmitt, Florian Scotté, Coralie Marjollet, Anne Floquet
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, 2022, 109 (12), pp.1245-1261. ⟨10.1016/j.bulcan.2022.06.011⟩
Bulletin du Cancer, 2022, 109 (12), pp.1245-1261. ⟨10.1016/j.bulcan.2022.06.011⟩
International audience; Objective > Despite an increasing number of therapeutic indications, there are no specific recommendations regarding the management of PARP inhibitors other than what is specified in the SmPC of each substance. A Delphi French
Publikováno v:
Bulletin Infirmier du Cancer. 23:5-7
Autor:
Frédéric, Selle, Jean-Jacques, Boffa, Gabriel, Etienne, Antoine, Angelergues, Paule, Augereau, Dominique, Berton, Pascale, Dielenseger, Michel, Fabbro, Claire, Falandry, Philippe, Follana, Laurence, Gladieff, Florence, Joly, Jean-Emmanuel, Kurtz, Carla, Matta, Marie-Ange, Mouret-Reynier, Antonin, Schmitt, Florian, Scotté, Coralie, Marjollet, Anne, Floquet
Publikováno v:
Bulletin du cancer. 109(12)
Despite an increasing number of therapeutic indications, there are no specific recommendations regarding the management of PARP inhibitors other than what is specified in the SmPC of each substance. A Delphi French consensus was conducted to establis
Autor:
Denis Moro-Sibilot, Jean-Baptiste Rey, Jerome Sicard, Pascale Dielenseger, René-Jean Bensadoun, Jaafar Bennouna, Marie Wislez, David Malka, Florian Scotté, Laurent Mortier
Publikováno v:
Bulletin du Cancer. 101:647-652
Tyrosine kinase inhibitors (TKI) that block epidermal growth factor receptor (EGFR) pathway have demonstrated a clinical benefit for patients with non-small-cell lung cancer (NSCLC) harboring EGFR mutations. The currently available TKI (gefitinib and
Publikováno v:
Annals of Oncology. 28:v547
Preventing CINV is possible when guideline-recommended antiemetics are used. Because oncology nurses play a critical role in risk assessment and management of CINV, a survey of European nurses was conducted to evaluate antiemetic practices, assess aw
Publikováno v:
Revue de l'infirmiere. (141)
Autor:
Pascale, Dielenseger, Jean-Marie, Dilhuydy, Sylvie, Brusco, Lucette, Chazot, Jean-Yves, Blay, Bertrand, Bové, Benoit, Colcanap, Jean-Claude, Ferrandez, Anne, Floquet, Jane Gledhill, Nicole, Hubert, Michèle, Meslier, Sophia, Rosman, Julien, Carretier, Valérie, Delavigne, Béatrice, Fervers, Line, Leichtnam-Dugarin, Thierry, Philip
Publikováno v:
Bulletin du cancer. 93(12)
In response to the evolution of the information-seeking behaviour of patients and concerns from health professionals regarding cancer patient information, the French National Federation of Comprehensive Cancer Centres (FNCLCC) introduced, in 1998, an
Autor:
Karin, Ahlberg, Pascale, Dielenseger, Shelley, Dolan, Jan, Foubert, Maria, Munoz, Jan, Ouwerkerk, Mary, Uhlenhopp, Debra, Wujcik
Publikováno v:
The journal of supportive oncology. 3(6 Suppl 4)
Publikováno v:
Douleurs : Evaluation - Diagnostic - Traitement. 12:H14-H15